Lyell Immunopharma (LYEL) EBITDA Margin Growth (1y) (2021 - 2026)
Powered by 
Analysis
Lyell Immunopharma (LYEL) EBITDA Margin Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -1,651.00 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 29,091.00 |
| 10 | Lyell Immunopharma | 335.97 Mn | 335.97 Mn | - | -59.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.42 Mn |
| Mar 31, 2026 | -139.35 Mn |
| Dec 31, 2025 | -29.88 Mn |
| Sep 30, 2025 | -9.98 Mn |
| Jun 30, 2025 | -19.29 Mn |
| Mar 31, 2025 | 103.30 Mn |
| Dec 31, 2024 | -137.09 Mn |
| Sep 30, 2024 | 8.76 Mn |
| Jun 30, 2024 | -15.23 Mn |
| Mar 31, 2024 | -175.63 Mn |
| Dec 31, 2023 | -45.77 Mn |
| Sep 30, 2023 | 197.84 Mn |
| Jun 30, 2023 | -24.40 Mn |
| Mar 31, 2023 | -8.38 Mn |
| Dec 31, 2022 | 165,400.00 |
| Sep 30, 2022 | -221.28 Mn |
| Jun 30, 2022 | 228,186.00 |
| Mar 31, 2022 | -1.01 Mn |
| Dec 31, 2021 | 2,497.00 |
| Sep 30, 2021 | 165,884.00 |